|View printer-friendly version|
|July 29, 2003 4:40 p.m.|
|Teva Reports Q2 EPS of $0.75 Including One Time Items$0.49 Before One Time Items - an Increase of 44% Q2 Sales Increased 34% to $764 Million|
Q2 Global in-market sales of Copaxone® totaled $176 million, up 35%Jerusalem, Israel, July 29, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income of $137 million before one-time items for the second quarter of 2003, or $210 million including one time items. Fully diluted EPS reached $0.49 before one time items, up 44%, or $0.75 including one time items. Net sales for the quarter increased 34% to $764 million, with continuing favorable currency trends accounting for close to one fifth of this increase.